We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+21.19%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$151M
AUM Growth
+$11.1M
Cap. Flow
+$7.92M
Cap. Flow %
5.24%
Top 10 Hldgs %
64.45%
Holding
47
New
17
Increased
12
Reduced
7
Closed
10

Top Buys

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$8.75M
2
CYTK icon
Cytokinetics
CYTK
+$7.84M
3
CABA icon
Cabaletta Bio
CABA
+$6.24M
4
SVRA icon
Savara
SVRA
+$6.04M
5
BBIO icon
BridgeBio Pharma
BBIO
+$5.01M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$17.7M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$8.69M
3
IMVT icon
Immunovant
IMVT
+$8.58M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.87M
5
LNTH icon
Lantheus
LNTH
+$3.4M

Sector Composition

Rank Sector Weight
1 Healthcare 96.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$10.9B
$19.6M 12.93%
278,915
+101,312
+57% +$7.84M
NKTX icon
2
Nkarta
NKTX
$186M
$12.9M 8.5%
1,189,193
+841,812
+242% +$8.75M
ETNB
3
DELISTED
89bio
ETNB
$11M 7.24%
941,287
-80,190
-8% -$888K
BBIO icon
4
BridgeBio Pharma
BBIO
$15.9B
$10.9M 7.23%
353,507
+147,181
+71% +$5.01M
SVRA icon
5
Savara
SVRA
$1.13B
$10.3M 6.8%
2,065,144
+1,250,878
+154% +$6.04M
IDYA icon
6
IDEAYA Biosciences
IDYA
$3.47B
$9.53M 6.3%
217,070
-34,225
-14% -$1.47M
FATE icon
7
Fate Therapeutics
FATE
$324M
$6.76M 4.47%
920,476
+72,653
+9% +$450K
DAWN
8
DELISTED
Day One Biopharmaceuticals
DAWN
$5.78M 3.82%
349,679
-29,947
-8% -$448K
ROIV icon
9
Roivant Sciences
ROIV
$24.8B
$5.6M 3.7%
531,019
+204,858
+63% +$2.21M
IONS icon
10
Ionis Pharmaceuticals
IONS
$8.99B
$5.24M 3.47%
120,896
-68,722
-36% -$3.28M
MRNS
11
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5.11M 3.38%
565,550
+103,106
+22% +$1M
CABA icon
12
Cabaletta Bio
CABA
$461M
$4.96M 3.28%
+290,797
New +$6.24M
URGN icon
13
UroGen Pharma
URGN
$1.96B
$4.32M 2.86%
288,267
+32,837
+13% +$537K
VRNA
14
DELISTED
Verona Pharma
VRNA
$4.17M 2.76%
259,383
+135,343
+109% +$2.34M
JBIO
15
Jade Biosciences
JBIO
$1.27B
$3.26M 2.16%
+3,150
New +$2.41M
APGE icon
16
Apogee Therapeutics
APGE
$10.1B
$2.98M 1.97%
+44,868
New +$1.96M
AXSM icon
17
Axsome Therapeutics
AXSM
$11.8B
$2.92M 1.93%
36,607
+20,428
+126% +$1.71M
DYN icon
18
Dyne Therapeutics
DYN
$3.92B
$2.83M 1.87%
+99,822
New +$2.26M
PRAX icon
19
Praxis Precision Medicines
PRAX
$8.77B
$2.45M 1.62%
+40,119
New +$1.8M
ALLO icon
20
Allogene Therapeutics
ALLO
$618M
$2.33M 1.54%
521,249
+299,137
+135% +$1.25M
KROS icon
21
Keros Therapeutics
KROS
$211M
$2.24M 1.48%
33,828
-40,821
-55% -$2.42M
PYXS icon
22
Pyxis Oncology
PYXS
$150M
$2.1M 1.39%
+493,759
New +$2.08M
ASND icon
23
Ascendis Pharma A/S
ASND
$17.1B
$1.93M 1.27%
+12,754
New +$1.82M
PEPG icon
24
PepGen
PEPG
$156M
$1.68M 1.11%
+114,385
New +$1.35M
TRML
25
DELISTED
Tourmaline Bio
TRML
$1.6M 1.06%
+69,972
New +$2.47M
1
2

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Superstring Capital Management held 47 positions worth $151M, up 7.9% from $140M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Superstring Capital Management deployed $7.92M of net new capital in Q1 2024, opening 17 new positions and adding to 12 existing holdings. Its largest new stake was Cabaletta Bio: 290,797 shares worth $4.96M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $3.28M trimmed.

  • Superstring Capital Management's largest Q1 2024 buy was Cabaletta Bio: 290,797 shares worth $4.96M.
  • Superstring Capital Management added most to Nkarta in Q1 2024, an estimated $8.75M increase.
  • Superstring Capital Management's biggest Q1 2024 reduction was Ionis Pharmaceuticals, cutting an estimated $3.28M.
  • Superstring Capital Management fully exited Immunogen Inc in Q1 2024, selling an estimated $17.7M.
  • Superstring Capital Management's ten largest holdings make up 64% of its $151M portfolio in Q1 2024.
  • Superstring Capital Management opened 17 new positions and closed 10 in Q1 2024.
  • Superstring Capital Management's portfolio value rose 7.9% quarter-over-quarter to $151M.

Based on Superstring Capital Management's 13F filing for Q1 2024, filed 15 May 2024.